Search

Displaying results 3601 - 3610 of 4246 in total
  1. Drug

    Human Umbilical Cord Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15726
    Investigational

    The cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the ‘standard’ thus far.

  2. Drug

    N-Acetylglucosamine

    go.drugbank.com/drugs/DB00141
    ApprovedInvestigationalNutraceutical

    The N-acetyl derivative of glucosamine.

  3. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    RGN6024, also known as RGN-6024 or RGNi6024, is a synthetic small-molecule tubulin destabilizer from Reglagene. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.

  4. Drug

    AICA ribonucleotide

    go.drugbank.com/drugs/DB01700
    Investigational

    The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity

  5. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.

  6. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  7. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome

  8. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  9. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility

  10. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    It is being developed as an adjunct to chemotherapy.